.Attribute Medicine, Published online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Perspective requires incorporation of individuals with MASLD and measurement of liver outcomes in cardio-- kidney-- metabolic trials, when records recommend mechanistically tenable advantages and scientific safety and security-- and describes considerations for trial concept and also regulative approval.